Literature DB >> 33758324

The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.

Claudia Cristina Biguetti1,2, Joel Ferreira Santiago Junior3, Matthew William Fiedler1, Mauro Toledo Marrelli1,4, Marco Brotto5.   

Abstract

The aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles. We designed the study according to PRISMA guidelines. Studies for qualitative and quantitative analyses were selected according to the following inclusion criteria: English language; size of sample (> 5 patients), adult (> age of 18) patients, treated with CQ/HCQ for inflammatory diseases, and presenting and not presenting with toxic effects on skeletal muscles. We collected data published from 1990 to April 2020 using PubMed, Cochrane Library, EMBASE, and SciELO. Risk of bias for observational studies was assessed regarding the ROBIN-I scale. Studies with less than five patients (case reports) were selected for an additional qualitative analysis. We used the software Comprehensive Meta-Analysis at the confidence level of 0.05. We identified 23 studies for qualitative analysis (17 case-reports), and five studies were eligible for quantitative analysis. From case reports, 21 patients presented muscle weakness and confirmatory biopsy for CQ/HCQ induced myopathy. From observational studies, 37 patients out of 1,367 patients from five studies presented muscle weakness related to the use of CQ/HCQ, and 252 patients presented elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase). Four studies presented data on 34 patients with confirmatory biopsy for drug-induced myopathy. No study presented randomized samples. The chronic use of CQ/HCQ may be a risk for drug-induced myopathy. There is substantiated need for proper randomized trials and controlled prospective studies needed to assess the clinical and subclinical stages of CQ/HCQ -induced muscle myopathy.

Entities:  

Year:  2021        PMID: 33758324     DOI: 10.1038/s41598-021-86079-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

1.  Hydroxychloroquine - How Much Is Too Much?

Authors:  Vaneet Kaur Sandhu; Michael H Weisman
Journal:  J Rheumatol       Date:  2019-04       Impact factor: 4.666

2.  Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.

Authors:  E Casado; J Gratacós; C Tolosa; J M Martínez; I Ojanguren; A Ariza; J Real; A Sanjuán; M Larrosa
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

3.  Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?

Authors:  Konstantinos Tselios; Mery Deeb; Dafna D Gladman; Paula Harvey; Shadi Akhtari; Susanna Mak; Jagdish Butany; Murray B Urowitz
Journal:  J Rheumatol       Date:  2018-10-15       Impact factor: 4.666

Review 4.  Quinolines and structurally related heterocycles as antimalarials.

Authors:  Kirandeep Kaur; Meenakshi Jain; Ravi P Reddy; Rahul Jain
Journal:  Eur J Med Chem       Date:  2010-04-18       Impact factor: 6.514

5.  Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties.

Authors:  David C Warhurst; Jonathan C P Steele; Ipemida S Adagu; John C Craig; Christopher Cullander
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

6.  Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.

Authors:  Thomas Khoo; Sophia Otto; Caroline Smith; Barbara Koszyca; Sue Lester; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2016-09-14       Impact factor: 2.980

Review 7.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

8.  Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.

Authors:  O P Sharma
Journal:  Arch Neurol       Date:  1998-09

Review 9.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 10.  Antimalarials - are they effective and safe in rheumatic diseases?

Authors:  Ewa Haładyj; Mariusz Sikora; Anna Felis-Giemza; Marzena Olesińska
Journal:  Reumatologia       Date:  2018-06-30
View more
  1 in total

Review 1.  Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.

Authors:  Luke R Gagnon; Chandu Sadasivan; Haran Yogasundaram; Gavin Y Oudit
Journal:  Curr Heart Fail Rep       Date:  2022-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.